Participated · Series B · Jul 2026

Crystalys is advancing dotinurad, a next-generation, once-daily oral URAT1 inhibitor positioned as a second-line therapy to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has regulatory approvals in Japan, China, the Philippines, Taiwan and Thailand, with supporting clinical data from those markets. The company is conducting the JEWEL clinical research program, which includes the Phase 3 RUBY and TOPAZ trials and the Phase 2 AMETHYST study to evaluate safety and efficacy across a broad spectrum of gout patients. Crystalys aims to position dotinurad as a best-in-class option for safety and efficacy and is preparing for global commercialization. The company is headquartered in San Diego and was co-founded by Catalys Pacific and Novo Holdings. With the announced $130 million Series B, Crystalys has increased its financial runway to support late-stage development and commercial readiness.

Participated · Series C · May 2026

Cerevance uses a proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify drug targets expressed in specific human brain cell types. Its lead investigational candidate, solengepras (CVN424), is a once-daily oral therapy being evaluated in the pivotal Phase 3 ARISE trial, which is fully enrolled with 341 patients. ARISE is a randomized, double-blind, placebo-controlled study assessing solengepras as an adjunctive therapy in patients with motor fluctuations; topline data are expected at the end of Q3 2026. The company also is developing CVN293, a selective oral inhibitor targeting THIK1 (KCNK13). Cerevance announced an oversubscribed $20 million Series C to fund operations through the ARISE readout and to advance its pipeline, extending runway into mid-2027. The company is clinical-stage and based in Boston.

Led · Series A · Dec 2025

PsiThera integrates biophysics, advanced computational modeling, and mechanistic biology to identify biologically relevant protein states and design optimized oral therapeutics targeting immune and inflammatory conditions. The company’s platform is intended to uncover novel therapeutic opportunities that traditional discovery approaches overlook. By focusing on protein conformations, PsiThera aims to create drugs with improved selectivity and efficacy. The organization is led by CEO Eric Shaff alongside Woody Sherman, Ph.D. (Chief Innovation Officer), Camil Sayegh, Ph.D. (Chief Scientific Officer), Jean-Christophe Harmange, Pharm.D., Ph.D. (SVP, Drug Discovery), and Kal Lapan, Ph.D. (VP, Head of Operations). The business plans to channel new capital into expanding its operations and advancing drug-development programs. PsiThera’s most recent financing—its $47.5 million Series A—provides the company’s current financial footing and resources for further growth.

Participated · Series A · Sep 2025

Alchemab Therapeutics is a clinical-stage biotech founded in 2019 that uses its Resiliome™ platform—combining one of the world’s largest fully human antibody databases with AI and lab validation—to identify naturally occurring protective antibodies from disease-resilient individuals. The company has generated a pipeline of first- and best-in-class antibody assets, including ATLX-1282, a first-in-class therapeutic in clinical development for ALS that was licensed to Eli Lilly. Alchemab plans to expand its proprietary antibody dataset from about 500 million sequences to over one billion and to advance additional candidates into clinical development. The company’s platform integrates deep sequencing, AI-derived algorithms, and laboratory validation to characterise candidate antibodies. Alchemab has raised a total of £109 million in Series A financing to date and lists investors such as SV Health Investors, the Dementia Discovery Fund, RA Capital, DCVC Bio, Eli Lilly, Lightstone Ventures, Ono Venture Investment, and Camford Partners. The recent £25 million Series A extension led by the British Business Bank is intended to accelerate its clinical pipeline and database growth.

Participated · Series B · Aug 2025

ProVerum Ltd. is a Dublin-based developer of the ProVee® System, an investigational, minimally invasive treatment for BPH. The ProVee System uses a nitinol stent designed to gently re-shape the enlarged prostate and alleviate lower urinary tract symptoms, and is delivered through a low-profile, flexible, steerable delivery system with integrated imaging. The device is investigational and, per the company, is limited by law to investigational use and not available for sale within the United States. ProVerum says proceeds from the financing will be used to prepare for commercialization. The company has emphasized preparing to commercialize its novel treatment for men with BPH as it advances development. Leadership changes accompanying the financing include additions to the board from investor partners.